The specialist cancer drug discovery and development business has regained worldwide rights to preclinical-stage small molecule inhibitors of Aurora and FLT3 kinases that have shown potential in acute myeloid leukaemia (AML) and other haematological cancers. The preclinical development candidate, to which Sareum regains the rights, has shown promise against a range of haematological cancer models including AML and Acute Lymphoblastic Leukaemia (ALL) with good tolerance of the candidate drug a ....